Observational studyClinical rheumatology2026
Lower odds of prevalent vertebral fractures with b/tsDMARD use among rheumatoid arthritis patients in clinical remission: a retrospective observational study.
Observational study in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mid-thoracic predominance and region-specific risk factors for vertebral fractures in rheumatoid arthritis: a cross-sectional study.Clinical rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesThis study investigated serum pentosidine levels as an advanced glycation end product (AGE)-related marker of bone matrix deterioration and examined the association between b/tsDMARD use and prevalent vertebral fractures in patients with RA in clinical remission.
methodsSeventy-six patients with RA in clinical remission (DAS28-CRP < 2.3) were included. Serum pentosidine, bone turnover markers, and bone mineral density (BMD) were assessed. Lateral thoracolumbar spine radiographs were available for 51 patients, and prevalent vertebral fractures were evaluated using artificial-intelligence-assisted morphometry, with final physician confirmation. Multivariable regression analyses evaluated factors associated with serum pentosidine levels and prevalent vertebral fractures.
resultsPatients receiving b/tsDMARDs had lower serum pentosidine levels (P = 0.004) despite comparable BMD and bone turnover marker profiles. In multivariable linear regression, DAS28-ESR was associated with serum pentosidine levels (β = 0.00581, P = 0.011), while b/tsDMARD use showed a non-significant trend toward lower serum pentosidine levels (β = - 0.00544, P = 0.091). Vertebral fractures were numerically less common in patients receiving b/tsDMARDs (2/19 [10.5%] vs 11/32 [34.4%]). In logistic regression, older age was associated with higher odds of prevalent vertebral fractures (odds ratio 1.211 per year, 95% CI 1.074-1.439; P < 0.001), while b/tsDMARD use was associated with lower odds (odds ratio 0.144, 95% CI 0.015-0.841; P = 0.030).
conclusionsIn patients with RA in clinical remission, b/tsDMARD use was associated with lower odds of prevalent vertebral fractures. Residual inflammation, reflected by DAS28-ESR and serum pentosidine levels, may be relevant to skeletal fragility beyond BMD. Key Points • Lower serum pentosidine levels were observed in b/tsDMARD-treated patients, whereas DAS28-ESR was independently associated with serum pentosidine levels in multivariable analysis. • In patients with rheumatoid arthritis in clinical remission, b/tsDMARD use was associated with lower odds of prevalent vertebral fractures. • Residual inflammation and bone matrix deterioration may be related to skeletal fragility beyond bone mineral density.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.